The influences of paclitaxel, calcitriol and cinacalcet on hemodialysis patients with CKD-MBD in real-world

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026679

Enrollment

Unknown

Registered

2019-10-18

Start date

2019-10-25

Completion date

Unknown

Last updated

2019-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease-mineral and bone disorder

Interventions

Paricalcitol group:take paricalcitol according to the condition

Calcitriol group:take calcitriol according to the condition

cinacalcet group:take cinacalcet according to the condition

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: hemodialysis patients with clinical diagnosis of secondary hyperparathyroidism

Exclusion criteria

Exclusion criteria: have drug contraindications

Design outcomes

Primary

Measure	Time frame
Percentage of iPTH decline;	—

Secondary

Measure	Time frame
T cell subsets, immunoglobulins, NF-Kb, Nrf2 expression of peripheral blood lymphocytes;Blood RT, Blood biochemical item, VitD, Ca, P, IL-1beta, IL-2, IL-6, IL-10, TNF-alpha, hs-CRP;AOPP, SOD, MDA, TP1NP, CROSSL, FGF23, Klotho;Coronary CT, parathyroid ultrasound, bone mineral density, Cardiac ultrasound, carotid ultrasound;	—

Countries

China

Contacts

Public ContactTongqiang Liu

The Affiliated Changzhou 2nd People's Hospital of Nanjing Medical University

liuyf1106@126.com+86 13775606952

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026